Enzene biosciences launches Ranibizumab to treat neovascular AMD – ET HealthWorld | Pharma

New Delhi: Pune-based Enzene Biosciences followed by the launch of Bevacizumab to treat metastatic colorectal cancer, as brought in Ranibizumab, a biosimilar to the breakthrough medication Lucentis®, which is marketed in India as Accentrix®. Ranibizumab is a recombinant Fab used as a treatment for neovascular age-related macular degeneration (AMD).The Ranibizumab biosimilar is the seventh biosimilar produced and could significantly lower treatment costs for thousands of Indian patients. As established in Phase 3 clinical studies, Enzene’s Ranibizumab biosimilar showed comparative clinical efficacy with Lucentis and is produced using the company’s state-of-the-art MAR system at its plant in Chakan, Pune.

Dr Himanshu Gadgil, CEO, Enzene Biosciences said, “Prior to Ranibizumab, our teams have successfully delivered six commercial biosimilars and supported our partners with clinical supplies of novel biologic entities (NBEs), such as monoclonal antibodies (mAbs) and multi-specific molecules. Additionally, we’ve pioneered the EnzeneX platform, a leading commercial continuous manufacturing platform. The successful commercialization of Ranibizumab, a recombinant Fab, stands as a testament to the exceptional skills of our technical teams.”

The company further stated that it is actively progressing with the development of three additional biosimilars in various stages. It is in alliance with UK-based pharmaceutical firm Theramex to launch a biosimilar of Prolia in Europe, UK, Australia, and Switzerland.

Enzene Biosciences is also developing a synthetic peptide pipeline and is focused on supplementing its manufacturing capabilities, with plans to expand into key international markets like the US, at a rapid pace.